Presence of activated T lymphocytes in peripheral blood of head and neck squamous cell carcinoma patients predicts impaired prognosis

Acta Oto-Laryngologica

Volumn 126, Issue 12, 2006, Pages 1326-1333

  Aarstad, Hans Jørgen ^a,b   Heimdal, John Helge ^a,b   Klementsen, Beate ^a   Olofsson, Jan ^a,b   Ulvestad, Elling ^b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Neoplasms; Prognosis; Squamous carcinoma; T lymphocyte activation

Indexed keywords

CD69 ANTIGEN; CD71 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSFERRIN RECEPTOR;

ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; CELL ACTIVATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; HEAD AND NECK CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; PROGNOSIS; T-LYMPHOCYTES;

EID: 33751085890     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.1080/00016480600702092     Document Type: Article

References (31)

1. Whiteside TL. Immune responses to malignancies. J Allergy Clin Immunol 2003;111:S677-86.
2. Whiteside TL. Immunobiology of head and neck cancer. Cancer Metastasis Rev 2005;24:95-105.
3. McKechnie A, Robins RA, Eremin O. Immunological aspects of head and neck cancer: biology, pathophysiology and therapeutic mechanisms. Surgeon 2004;2:187-207.
4. Bauernhofer T, Kuss I, Henderson B, Baum AS, Whiteside TL. Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol 2003;33:119-24.
5. Kross KW, Heimdal JH, Olsnes C, Olofsson J, Aarstad HJ. Head and neck squamous cell carcinoma spheroid- and monocyte spheroid-stimulated IL-6 and monocyte chemotactic protein-1 secretion are related to TNM stage, inflammatory state and tumor macrophage density. Acta Otolaryngol (Stockh) 2005;125:1097-104.
6. Olsnes C, Heimdal JH, Kross KW, Olofsson J, Aarstad HJ. Viable head and neck tumor spheroids stimulate in vitro autologous monocyte MCP-1 secretion through soluble substances and CD14/lectin-like receptors. Eur Arch Otorhinolaryngol 2005;262:953-60.
7. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10:3755-62.
8. Heimdal JH, Aarstad HJ, Olofsson J. Peripheral blood T-lymphocyte and monocyte function and survival in patients with head and neck carcinoma. Laryngoscope 2000;110: 402-7.
9. Caruso A, Licenziati S, Corulli M, Canaris AD, De-Francesco MA, Fiorentini S, et al. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry 1997;27:71-6.
10. Tartour E, Mosseri V, Jouffroy T, Deneux L, Jaulerry C, Brunin F, et al. Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet 2001;357:1263-4.
11. Reddy M, Eirikis E, Davis C, Davis HM, Prabhakar U. Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function. J Immunol Methods 2004;293:127-42.
12. Crispin JC, Martinez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2003;21:273-6.
13. Meloni F, Vitulo P, Bianco AM, Paschetto E, Morosini M, Cascina A, et al. Regulatory CD4+CD25+ T cells in the peripheral blood of lung transplant recipients: correlation with transplant outcome. Transplantation 2004;77:762-6.
14. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002;169: 3400-6.
15. Jones GW, Browman G, Goodyear M, Marcellus D, Hodson DI. Comparison of the addition of T and N integer scores with TNM stage groups in head and neck cancer. Head Neck 1993;15:497-503.
16. Gonzalez FM, Vargas JA, Gea-Banacloche JC, Garcia JR, Berrocal E, Gorriz C, et al. Functional and phenotypic analysis of T-lymphocytes in laryngeal carcinoma. Acta Otolaryngol (Stockh) 1994;114:663-8.
17. Kim JW, Tsukishiro T, Johnson JT, Whiteside TL. Expression of pro- and antiapoptotic proteins in circulating CD8+ T cells of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10:5101-10.
18. Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 2005;92:913-20.
19. Saito T, Kuss I, Dworacki G, Gooding W, Johnson JT, Whiteside TL. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res 1999;56:1263-73.
20. Pavlicek J, Sopko B, Ettrich R, Kopecky V Jr, Baumruk V, Man P, et al. Molecular characterization of binding of calcium and carbohydrates by an early activation antigen of lymphocytes CD69. Biochemistry 2003;42:9295-306.
21. Marzio R, Mauel J, Betz Corradin S. CD69 and regulation of the immune function. Immunopharmacol Immunotoxicol 1999;21:565-82.
22. Posselt AM, Vincenti F, Bedolli M, Lantz M, Roberts JP, Hirose R. CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients. Transplantation 2003;76:190-5.
23. Whiteside TL. Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 2004;53:865-78.
24. Reichert TE, Day R, Wagner EM, Whiteside TL. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 1998;58:5344-7.
25. Nakamura H, Idiris A, Kato Y, Kato H. An increase in the percentage of HLA-DR-positive peripheral leukocytes predicts a poor prognosis in patients with squamous cell carcinoma of the lung. Oncol Rep 2004;11:673-6.
26. Nakamura H, Saji H, Aute I, Kawasaki N, Hosaka M, Ogata A, et al. Peripheral leukocytes with HLA-DR+/CD8-phenotype are associated with prognosis in patients with lung cancer. Anticancer Res 2003;23:4149-52.
27. Nakamura H, Saji H, Ogata A, Hosaka M, Hagiwara M, Kawasaki N, et al. Immunologic parameters as significant prognostic factors in lung cancer. Lung Cancer 2002;37: 161-9.
28. Niitsu N, Iijima K, Chizuka A. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Eur J Haematol 2001;66:24-30.
29. Vuoristo MS, Laine S, Huhtala H, Parvinen LM, Hahka-Kemppinen M, Korpela M, et al. Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma. Eur J Cancer 2001;37:1629-34.
30. Van Belle SJ, Cocquyt V. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 2003;47:1-11.
31. Hoffmann TK, Bier H, Whiteside TL. Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2004;53:1055-67.